News: Salix Announces Appointment of Mark Sirgo to Board of …
Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the
appointment of Mark A. Sirgo, Pharm. D., to the Company’s Board of
Directors.
Dr. Sirgo has over 25 years pharmaceutical industry experience
spanning clinical drug development, executive management, business
development, marketing and sales. He currently serves as President and
Chief Executive Officer of BioDelivery Sciences International
(NASDAQ:BDSI), and previously held positions with Arius
Pharmaceuticals, Pharmaceutical Product Development (PPD) and
GlaxoSmithKline. Dr. Sirgo received his BS in Pharmacy from The Ohio
State University and his Doctorate from Philadelphia College of
Pharmacy and Science.
“We are very pleased to welcome Mark to the Salix Board,”
commented John Chappell, Chairman, Salix Pharmaceuticals. “Mark’s
depth and breadth of experience and skills, particularly his proven
abilities in the oversight and execution of clinical development,
should serve the Board and Company well. We look forward to Mark’s
contributions.”
Salix Pharmaceuticals, Ltd., headquartered in Raleigh, North
Carolina, develops and markets prescription pharmaceutical products
for the treatment of gastrointestinal diseases. Salix’s strategy is to
in-license late-stage or marketed proprietary therapeutic drugs,
complete any required development and regulatory submission of these
products, and market them through the Company’s gastroenterology
specialty sales and marketing team.
Salix markets COLAZAL(R) (balsalazide disodium) Capsules 750 mg,
XIFAXAN(R) (rifaximin) tablets 200 mg , OSMOPREP(R) (sodium phosphate
monobasic monohydrate, USP and sodium phosphate dibasic anhydrous,
USP) Tablets, MOVIPREP(R) (PEG 3350, Sodium Sulfate, Sodium Chloride,
Potassium Chloride, Sodium Ascorbate and Ascorbic Acid for Oral
Solution), VISICOL(R) (sodium phosphate monobasic monohydrate, USP,
and sodium phosphate dibasic anhydrous, USP) Tablets, PEPCID(R)
(famotidine) for Oral Suspension, Oral Suspension DIURIL(R)
(Chlorothiazide), AZASAN(R) Azathioprine Tablets, USP, 75/100 mg ,
ANUSOL-HC(R) 2.5% (Hydrocortisone Cream, USP), ANUSOL-HC(R) 25 mg
Suppository (Hydrocortisone Acetate), PROCTOCORT(R) Cream
(Hydrocortisone Cream, USP) 1% and PROCTOCORT(R) Suppository
(Hydrocortisone Acetate Rectal Suppositories) 30 mg. Current
development projects include balsalazide tablet,
metoclopramide-Zydis(R), encapsulated mesalamine granules, vapreotide
acetate, and rifaximin for additional indications.
For full prescribing information on Salix products, please visit
www.salix.com or contact the Company at 919 862-1000.
Salix trades on the NASDAQ Global Select Market under the ticker
symbol “SLXP.”
For more information please visit our web site at www.salix.com.
Information on our web site is not incorporated in our SEC filings.
Please Note: This press release contains forward-looking
statements regarding future events. These statements are just
predictions and are subject to risks and uncertainties that could
cause the actual events or results to differ materially. These risks
and uncertainties include risks of regulatory review and clinical
trials, potential generic and other competition, market acceptance for
approved products, intellectual property risks, the need to acquire
additional products and management of rapid growth. The reader is
referred to the documents that the Company files from time to time
with the Securities and Exchange Commission.
